Mark J. Foley, CEO at Revance Therapeutics, Inc. (RVNC), bought 40,000 shares at $12.90 ($516K) on 2021-11-29, disclosed to the SEC on 2021-11-29.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| GKOS | SELL | 2024-02-26 | $847K | — | Filing → |
| RVNC | SELL | 2023-08-04 | $1.2M | — | Filing → |
| RVNC | SELL | 2023-07-05 | $1.3M | — | Filing → |